Buprenorphine

Emplicure AB and Quotient Sciences Announce an Integrated Manufacturing and Clinical Testing Partnership for Emplicure's First Clinical Pharmacokinetic Study for EMPLI03

Retrieved on: 
Tuesday, November 29, 2022
Quotient, Doctor of Philosophy, Science, PK, Buprenorphine, Pain, Partnership, Chronic pain, Patient, Drug development, GMP, Pharmaceutical industry

The partnership will see Quotient Sciences support the GMP manufactureand first clinical pharmacokinetic (PK) study for EMPLI03 using itsunique Translational Pharmaceutics platform.

Key Points: 
  • The partnership will see Quotient Sciences support the GMP manufactureand first clinical pharmacokinetic (PK) study for EMPLI03 using itsunique Translational Pharmaceutics platform.
  • Quotient Sciences' integrated Translational Pharmaceutics platform has been used to establish the GMP manufacturing process for EMPLI03 and to perform the first clinical PK study.
  • Quotient Sciences introduced its Translational Pharmaceutics platform in 2008 as a fully integrated drug development and clinical testing platform.
  • Quotient Sciences is a drug development and manufacturing accelerator providing integrated programs and tailored services across the entire development pathway.

Bicycle Health Announces Significant Milestones for 2022, Laying the Foundation for Long-term Growth

Retrieved on: 
Tuesday, November 15, 2022
Behavior, Acquisition, Insurance, Opioid, MAT, Patient, Addiction, Business, Opioid use disorder, FDA, Buprenorphine, OUD, Pharmaceutical industry, Health insurance

Expanded its ability to treat patients to 29 new states, with plans to operate in 35 states by early 2023.

Key Points: 
  • Expanded its ability to treat patients to 29 new states, with plans to operate in 35 states by early 2023.
  • Grown the Bicycle Health team by 134%, including two senior executive hires, CTO Chris Norris and CCO Justin Guadagno.
  • We founded Bicycle Health to bring effective opioid use disorder treatment to all who need it regardless of geographic location or financial limitations.
  • In 2022, we took significant steps toward making that vision a reality, said Ankit Gupta, founder and CEO, Bicycle Health.

Global Opioids Market Report 2022: Featuring Purdue, Johnson & Johnson, Hikma Pharmaceuticals, Pfizer, Abbvie, Sanofi, Sun Pharmaceutical, Grunenthal & Merck - ResearchAndMarkets.com

Retrieved on: 
Wednesday, November 16, 2022
FDA, Pharmaceutical, Health, Purdue Pharma, FDA, Steroid, Prevalence, Analgesic, Morphine, Tablet, Chronic pain, Ibuprofen, Aspirin, Pain, Pain management, Nonsteroidal anti-inflammatory drug, Buprenorphine, Paracetamol, Patient, Route of administration, Segmental analysis (biology), Addiction, Arogyavani (104 Health Helpline Number), USD, Administration, Intrathecal administration, Substance, American Society of Anesthesiologists, Growth, Pharmacy, HHS, Codeine, Market share, Tramadol, Nalmefene, Pharmaceutical industry, Poultry, Coal, Application, Anesthesia

Emergence of non-addictive alternative products to opioids for pain-management leads to decline in the growth of opioid market. According to American Society of Anesthesiologists, there are several non-opioid medicines that are available over the counter--steroids and NSAIDs such as aspirin, ibuprofen, and acetaminophen among others. Furthermore, wide availability and low cost associated with these drugs contribute to increase in demand for such products during the forecast period. For instance, aspirin cost USD 10 for a pack of 30 tablets.

Key Points: 
  • The global opioids market size is expected to reach USD 25.33 billion by 2030, registering CAGR of 1.2% during the forecast period.
  • Growing use of opioids for the management of post-operative pain, caused due to surgeries, is expected to drive the market growth.
  • Emergence of non-addictive alternative products to opioids for pain-management leads to decline in the growth of opioid market.
  • The growth of the region can be attributed to increasing geriatric population which are susceptible to the chronic pain
    Chapter 4 Global Opioids Market - Segment Analysis, By Product, 2018 - 2030 (USD Million)
    Chapter 5 Global Opioids Market - Segment Analysis, by Application, 2018 - 2030 (USD Million)
    Chapter 6 Global Opioids Market - Segment Analysis, by Route of Administration, 2018 - 2030 (USD Million)
    Chapter 7 Global Opioids Market - Segment Analysis, by Distribution Channel, 2018 - 2030 (USD Million)
    Chapter 9 Global Opioids Market: Competitive Analysis

Lyndra Therapeutics’ LYNX™ Drug Delivery Platform Wins 2022 Fierce Life Sciences Innovation Award for Drug Delivery Technology

Retrieved on: 
Tuesday, November 15, 2022
Health, Other Science, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, SVP, Fierce, Fast Track, FDA, Malaria, GMP, Chicago Innovation Awards, Opioid use disorder, AbbVie, Engineering, Therapy, Thought disorder, Gilead Sciences, Pivotal, CNS, Research, Ivermectin, Face, NIH, Bill, Central nervous system, Public health, Schizophrenia, Buprenorphine, Patient, Pharmaceutical industry, Fine chemical

Lyndra Therapeutics today announced that its LYNX drug delivery platform was named the winner of the Fierce Life Sciences Innovation Awards 2022 award in the Drug Delivery Technology category.

Key Points: 
  • Lyndra Therapeutics today announced that its LYNX drug delivery platform was named the winner of the Fierce Life Sciences Innovation Awards 2022 award in the Drug Delivery Technology category.
  • It is an honor to have the platform selected by the Fierce award judges in such a competitive category.
  • The Fierce Life Sciences Innovation Awards, produced by Fierce Biotech and Fierce Pharma, showcase outstanding innovations that are transforming the life sciences industry.
  • The LYNX drug delivery platform harnesses more than 50 patented innovations in design, engineering and materials science to achieve dramatically reduced dosing frequency.

Ibogaine by David Dardashti Demonstrates Ongoing Success in Getting Users Off Suboxone, Methadone, and Fentanyl Without Requiring Short-Acting Opiates

Retrieved on: 
Thursday, November 24, 2022
Addiction, Depression, Life, Habit, ISBD, Happiness, Medical college, Buprenorphine, Pain, Physiology, International Society for Bipolar Disorders, Substance abuse, Medicine, Oxycodone, Subconscious, Trauma, Research, Panamerican University, Anxiety, Methadone, Ibogaine, Fear, Fentanyl, School, Mystery, Addictive Behaviors, Kabbalah, International Society of Sculptors, Painters and Gravers, Hospital, Pharmaceutical industry, Psychiatry, Affect (psychology), Talmud, Morphine

BOSTON, Nov. 23, 2022 /PRNewswire/ -- In the continuous fight against substance abuse across the continent, one ibogaine treatment center in Mexico has differentiated itself with proven protocols – designed to be tailored to individuals' unique needs – that have been shown to heal addiction and curb withdrawal.

Key Points: 
  • "The specific protocols we have been developing over 12 years have allowed us to see individuals respond extremely well long term to the ibogaine treatment."
  • Rabbi David Dardashti's facility is one of the only ibogaine facilities to publicly post direct and recent experiences from individuals who have experienced the treatment, in their own words.
  • Rabbi David Dardashti has dedicated his life to understanding the keys to human potential, happiness, and self-discovery.
  • Specializing in the study of Affective and Bipolar Disorders, her expertise is instrumental in helping people improve their lives.

Global Opioid Use Disorder Market Report to 2031 - Featuring Alkermes, AstraZeneca, BioDelivery Sciences International and Camurus Among Others - ResearchAndMarkets.com

Retrieved on: 
Thursday, November 10, 2022
Health, Pharmaceutical, Codeine, Drug, OUD, Cardiovascular disease, Methadone, Fentanyl, Age, Opioid use disorder, Breast, Conditional sentence, Knee, Injection, Lung cancer, Incidence, Population, Buprenorphine, Porter's five forces analysis, Oxycodone, Neurological disorder, Cancer, World Cancer Research Fund International, Morphine, Joint, Self-control, Benchmarking, Distribution, Journal, Motivation, Patient, Pain, Breast cancer, Growth, Administration, Hydrocodone, JAMA Network Open, The New England Journal of Medicine, Opioid, Route of administration, Injury, CAGR, Pharmaceutical industry, Cereal, Dentistry, Retail

Opioid usage disorder (OUD) is a chronic, relapsing brain disorder that is characterized by obsessive opioid seeking and use despite negative effects.

Key Points: 
  • Opioid usage disorder (OUD) is a chronic, relapsing brain disorder that is characterized by obsessive opioid seeking and use despite negative effects.
  • Opioid use disorder consists of an overpowering desire to use opioids, increased opioid tolerance, and withdrawal syndrome when discontinued.
  • This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the opioid use disorder market analysis from 2021 to 2031 to identify the prevailing opioid use disorder market opportunities.
  • The report includes the analysis of the regional as well as global opioid use disorder market trends, key players, market segments, application areas, and market growth strategies.

Acadia Healthcare Set to Open Four New Comprehensive Treatment Centers

Retrieved on: 
Tuesday, November 8, 2022
General Health, Health, Mental Health, Buprenorphine, Opioid addiction treatment in United States prisons, Patient, CTC, State, Health care, Chinese, The Sundays, Brand New, MAT, Acadia Healthcare, Heroin, Methadone, Dignity, Multimedia, Bed, Hospital, Pharmaceutical industry

Acadia Healthcare, a leading provider of behavioral healthcare services, is accepting new patients at its four new Comprehensive Treatment Centers (CTCs) in Georgia.

Key Points: 
  • Acadia Healthcare, a leading provider of behavioral healthcare services, is accepting new patients at its four new Comprehensive Treatment Centers (CTCs) in Georgia.
  • View the full release here: https://www.businesswire.com/news/home/20221107006188/en/
    Acadia recently acquired the four CTCs from Georgia-based Brand New Start Treatment Centers.
  • The four outpatient treatment centers, which are all located within 40 miles of Atlanta, are:
    We are excited to have the opportunity to play a critical role in ending the opioid epidemic in our community, said Erin McCarthy, regional vice president of Comprehensive Treatment Centers.
  • With more than 22,500 employees serving approximately 70,000 patients daily, Acadia is the largest stand-alone behavioral healthcare company in the U.S. Acadia provides behavioral healthcare services to its patients in a variety of settings, including inpatient psychiatric hospitals, specialty treatment facilities, residential treatment centers and outpatient clinics.

Clinical Evaluation of Aptinyx's NYX-783 for Treatment of Opioid Use Disorder to Be Funded by $5.6 Million NIH Grant

Retrieved on: 
Thursday, November 3, 2022
Biotechnology, Neurology, Health, Pharmaceutical, Clinical Trials, Blood pressure, Yale School of Medicine, Central nervous system, Annual report, Initiative, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, NIDA, Private Securities Litigation Reform Act, Research, Foundation, Food, NMDA, Form 10-K, Yale University, Human, Inc., HEAL, Connective tissue disease, Safety, Respiratory rate, Brain, Heart rate, APTX, Addictive behavior, National, Trial of the century, Nasdaq, Opioid, Post-traumatic stress disorder, Methadone, National Institute, Opioid use disorder, Buprenorphine, U.S. Securities and Exchange Commission, Oxycodone, Fast Track, Government budget balance, National Institute on Drug Abuse, Addiction, Rainforest Foundation Fund, OUD, Psychiatry, NIH, Drug, PTSD, Fentanyl, Patient, Naltrexone, Pharmacokinetics, Program, Pharmaceutical industry

NYX-783 is an NMDA receptor positive allosteric modulator also in Phase 2b development by Aptinyx for the treatment of post-traumatic stress disorder (PTSD).

Key Points: 
  • NYX-783 is an NMDA receptor positive allosteric modulator also in Phase 2b development by Aptinyx for the treatment of post-traumatic stress disorder (PTSD).
  • Additional preclinical research has demonstrated NYX-783s potential as a treatment option for the millions of people struggling with opioid use disorder.
  • We are pleased to continue our collaboration with Aptinyx for the evaluation of NYX-783 for the treatment of OUD, said Dr. DiLeone.
  • The company has multiple product candidates in clinical development in central nervous system indications, including cognitive impairment, post-traumatic stress disorder, and opioid use disorder.

State of Wisconsin to Provide Access to Prescription Digital Therapeutics to Help Local Communities Fight Against Addiction Crisis

Retrieved on: 
Thursday, November 3, 2022
Biotechnology, General Health, FDA, Health, Pharmaceutical, Health, FDA, Population, Pharmacoeconomics, Speech disorder, Policy by press release, DOI, BA, PDT, Substance abuse, Treatment, Buprenorphine, Comparison, Journal, Reading, Current Medical Research and Opinion, Substance use disorder, Language isolate, Wisconsin Department of Health Services, Pear, Williams–Campbell syndrome, Postgraduate Medicine, Safety, SUD, ClinicoEconomics and Outcomes Research, OUD, MBA, Cognitive behavioral therapy, Doctor of Philosophy, Insomnia, PEAR, Policy, Digital, Hospital Practice, Journal of Medical Economics, Digital therapeutics, Initiation, DHS, Smartphone, Randomized controlled trial, Therapy, Suicidal ideation, Reset, Risk, Opioid use disorder, MD, Pharmaceutical industry, Birth control, Hospital, Mobile phone, Medical device, Health insurance, Patient, Nasdaq

Eligible patients will be prescribed and treated with reSET or reSET-O to help communities throughout Wisconsin expand access to addiction care.

Key Points: 
  • Eligible patients will be prescribed and treated with reSET or reSET-O to help communities throughout Wisconsin expand access to addiction care.
  • The state of Wisconsin is making a difference for those struggling with addiction by expanding access to evidence-based treatment and recovery services, said Julia Strandberg, Chief Commercial Officer of Pear Therapeutics.
  • Reduced Healthcare Resource Utilization in Patients with Opioid Use Disorder in the 12 Months After Initiation of a Prescription Digital Therapeutic.
  • Evaluation of real-world outcomes associated with use of a prescription digital therapeutic to treat substance use disorders.

IntelGenx Receives FDA GDUFA Date for Xiromed-Partnered Development Candidate, Buprenorphine Buccal Film

Retrieved on: 
Tuesday, October 25, 2022
Physician, U.S. Securities and Exchange Commission, Drug Quality and Security Act, Review, TSX, LLC, Securities Exchange Act of 1934, Health, Patient, IMS Health, Inhalation, Annual report, Securities Act of 1933, Partnership, R, Form 10-K, Food, ANDA, Food and Drug Administration, Buprenorphine, CEO, Pain, IP, IGX, GLOBE, FDA, Risk, Generic drug, Pharmaceutical industry, Fine chemical

Buprenorphine Buccal Film is a generic version of Belbuca, an opioid that is used to manage pain severe enough to require daily, around-the-clock, long-term treatment with an opioid, when other pain treatments are inadequate.

Key Points: 
  • Buprenorphine Buccal Film is a generic version of Belbuca, an opioid that is used to manage pain severe enough to require daily, around-the-clock, long-term treatment with an opioid, when other pain treatments are inadequate.
  • Buprenorphine Buccal Film incorporates IntelGenxs VersaFilm technology in a novel formulation.
  • The companies co-developed the candidates ANDA that is currently under review by the FDA.
  • We are looking forward to the FDAs decision and, assuming a positive outcome, the commercialization of Buprenorphine Buccal Film as soon as possible.